Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need-Reference-Cited by-同舟云学术

Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need

Published:2021-02-02 Issue:1 Volume:6 Page:
ISSN:2059-3635
Container-title:Signal Transduction and Targeted Therapy
language:en
Short-container-title:Sig Transduct Target Ther

Author:

Jin Pengfei,Li Jingxin,Pan Hongxing,Wu Yanfei,Zhu Fengcai

Abstract

AbstractIn response to the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic, over 200 vaccine candidates against coronavirus disease 2019 (COVID-2019) are under development and currently moving forward at an unparalleled speed. The availability of surrogate endpoints would help to avoid large-scale filed efficacy trials and facilitate the approval of vaccine candidates, which is crucial to control COVID-19 pandemic. Several phase 3 efficacy trials of COVID-19 vaccine candidates are under way, which provide opportunities for the determination of COVID-19 correlates of protection. In this paper, we review current knowledge for existence of COVID-19 correlates of protection, methods for assessment of immune correlates of protection and issues related to COVID-19 correlates of protection.

Funder

Jiangsu Province Special Funds for Key Research & Developmen

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics

Link

http://www.nature.com/articles/s41392-021-00481-y.pdf

Reference62 articles.

1. World Health Organization. Draft landscape of COVID-19 candidate vaccines. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines (2020).

2. Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603–2615 (2020).

3. Baden L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2035389 (2020).

4. Voysey, M. et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. https://doi.org/10.1016/S0140-6736(20)32661-1 (2020).

5. Gamaleya National Center. The Sputnik V vaccine’s efficacy is confirmed at 91.4% based on data analysis of the final control point of clincial trials. https://sputnikvaccine.com/newsroom/pressreleases/the-sputnik-v-vaccine-s-efficacy-is-confirmed-at-91-4-based-on-data-analysis-of-the-final-control-po/ (2020).

Cited by 77 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Retrospective study about clinical severity and epidemiological analysis of the COVID-19 Omicron subvariant lineage-infected patients in Hohhot, China;BMC Infectious Diseases;2024-02-15

2. COVID-19 vaccination prevents a more severe course and treatment with complement inhibitors reduce worsening hemolysis during the Omicron pandemic in patients with PNH: a single-center study;Annals of Medicine;2023-12-12

3. Immunogenicity of COVID-19 vaccines in lung cancer patients;Lung Cancer;2023-10

4. Retrospective study about clinical severity and epidemiological analysis of the SARS-CoV-2 Omicron subvariant lineage-infected patients in Hohhot, China;2023-09-29

5. Evaluation of Quantitative IgG and Interferon-Gamma Responses After Different Booster Strategies of CoronaVac and BNT162b2 Vaccines in Turkey;2023-08-24